Table 1

Antitumor effectiveness of single mIL-12 gene electrotransfer alone or combined with irradiation on SA-1 sarcoma
Therapeutic group N DT (days; AM ± SE)* GD (days; AM ± SE)** Cures(%; n) SC resistance#
Control 12 1.7 ± 0.2 - 0
EP 13 4.2 ± 0.6 2.5 ± 0.6 0
dsRed 12 3.1 ± 0.3 1.3 ± 0.3 0
EGT dsRed 14 5.3 ± 0.9 3.5 ± 0.9 0
mIL-12 13 3.1 ± 0.4 1.4 ± 0.4 0
EGT mIL12 14 20.0 ± 3.0 18.3 ± 3.0 7.1 (1/14) 0/1
IR 13 5.4 ± 0.9 3.7 ± 0.9 0
EP + IR 14 14.4 ± 4.2 12.7 ± 4.2 0
dsRed + IR 9 5.3 ± 1.1 3.6 ± 1.1 0
EGT dsRed + IR 11 9.3 ± 1.9 7.5 ± 1.9 0
mIL-12 + IR 13 10.7 ± 1.7 8.9 ± 1.7 0
EGT mIL-12 + IR 14 32.6 ± 4.3 § 30.9 ± 4.3 § 21.4 (3/14) 1/3

Therapeutic groups: 10 Gy single dose irradiation (IR), electrical pulse application alone (EP) or combined with irradiation (EP + IR), intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (mIL-12, dsRed) or combined with irradiation (mIL-12 + IR, dsRed + IR), mIL-12 or dsRed gene electrotransfer alone (EGT mIL-12, EGT dsRed) or combined with irradiation (EGT mIL-12 + IR, EGT dsRed + IR).

N - Number of all mice in the group.

* - Tumor doubling time - only mice with tumors were included in calculation.

** - Tumor growth delay - only mice with tumors were included in calculation.

- Cures were determined 100 days after the treatment.

# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.

- Statistical significant difference compared to control group (p < 0.05).

§ - Statistical significant difference compared to IR (p < 0.05).

Sedlar et al.

Sedlar et al. BMC Cancer 2013 13:38   doi:10.1186/1471-2407-13-38

Open Data